GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of GMA-161. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of GMA-161. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of GMA-161. |
| Estrone | Estrone may increase the thrombogenic activities of GMA-161. |
| Estradiol | Estradiol may increase the thrombogenic activities of GMA-161. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of GMA-161. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of GMA-161. |
| Mestranol | Mestranol may increase the thrombogenic activities of GMA-161. |
| Estriol | Estriol may increase the thrombogenic activities of GMA-161. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of GMA-161. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of GMA-161. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of GMA-161. |
| Tibolone | Tibolone may increase the thrombogenic activities of GMA-161. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of GMA-161. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of GMA-161. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of GMA-161. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of GMA-161. |
| Zeranol | Zeranol may increase the thrombogenic activities of GMA-161. |
| Equol | Equol may increase the thrombogenic activities of GMA-161. |
| Promestriene | Promestriene may increase the thrombogenic activities of GMA-161. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of GMA-161. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of GMA-161. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of GMA-161. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of GMA-161. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of GMA-161. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of GMA-161. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of GMA-161. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of GMA-161. |
| Formononetin | Formononetin may increase the thrombogenic activities of GMA-161. |
| Estetrol | Estetrol may increase the thrombogenic activities of GMA-161. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with GMA-161. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with GMA-161. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with GMA-161. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with GMA-161. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with GMA-161. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with GMA-161. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with GMA-161. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with GMA-161. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with GMA-161. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with GMA-161. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with GMA-161. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with GMA-161. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with GMA-161. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GMA-161. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with GMA-161. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with GMA-161. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with GMA-161. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with GMA-161. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with GMA-161. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with GMA-161. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with GMA-161. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with GMA-161. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with GMA-161. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with GMA-161. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with GMA-161. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with GMA-161. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with GMA-161. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with GMA-161. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with GMA-161. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with GMA-161. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with GMA-161. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with GMA-161. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with GMA-161. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with GMA-161. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with GMA-161. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with GMA-161. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with GMA-161. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with GMA-161. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with GMA-161. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with GMA-161. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with GMA-161. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with GMA-161. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with GMA-161. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with GMA-161. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with GMA-161. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with GMA-161. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with GMA-161. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with GMA-161. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with GMA-161. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with GMA-161. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with GMA-161. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with GMA-161. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with GMA-161. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with GMA-161. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with GMA-161. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with GMA-161. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with GMA-161. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with GMA-161. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with GMA-161. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with GMA-161. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with GMA-161. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with GMA-161. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with GMA-161. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with GMA-161. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with GMA-161. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with GMA-161. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with GMA-161. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with GMA-161. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with GMA-161. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with GMA-161. |